United States — Food and Drug Administration & Robbins LLP
6 shared events · Importance 3 · Last updated Aug 21, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — Food and Drug Administration: The FDA placed a full clinical hold on ARD-101's IND, halting all ongoing studies. This regulatory action is central to the lawsuit and has severely impacted Aardvark's operations and stock price.
Robbins LLP: Robbins LLP is a shareholder rights law firm that announced the class action and is seeking lead plaintiffs. The firm represents investors on a contingency basis and may recover fees if the case succeeds.
Aug 14, 2026 · 23 articles
Regulatory
United States — Food and Drug Administration: The FDA rejected Replimune's BLA and published briefing documents raising concerns about the data package, triggering the stock drop and subsequent lawsuits. The FDA's actions are central to the event.
Robbins LLP: Robbins LLP is involved in the class action lawsuit against Replimune, reminding investors of the lead plaintiff deadline.
Jul 29, 2026 · 65 articles
Regulatory
United States — Food and Drug Administration: Regulator whose briefing documents and advisory committee vote triggered the stock collapse and legal actions.
Robbins LLP: Law firm that reminded investors of the class action lawsuit.
Jul 27, 2026 · 293 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Robbins LLP interact across events, view sentiment trends, and discover connected entities.
Open Dashboard